147 related articles for article (PubMed ID: 3093022)
1. Does 24R,25(OH)2-vitamin D3 prevent postmenopausal bone loss?
Riis BJ; Thomsen K; Christiansen C
Calcif Tissue Int; 1986 Sep; 39(3):128-32. PubMed ID: 3093022
[TBL] [Abstract][Full Text] [Related]
2. Treatment with vitamin 24,25 (OH)2D3 does not change serum levels of 1,25 (OH)2D or urinary calcium excretion rate in man.
Thomsen K; Riis BJ; Hummer L; Christiansen C
Acta Vitaminol Enzymol; 1985; 7(3-4):167-71. PubMed ID: 3879105
[TBL] [Abstract][Full Text] [Related]
3. Comparison of vitamin D metabolism in early healthy and late osteoporotic postmenopausal women.
Hartwell D; Riis BJ; Christiansen C
Calcif Tissue Int; 1990 Dec; 47(6):332-7. PubMed ID: 2292078
[TBL] [Abstract][Full Text] [Related]
4. Bone turnover in rats treated with 1,25-dihydroxyvitamin D3, 25-hydroxyvitamin D3 or 24,25-dihydroxyvitamin D3.
Mortensen BM; Gautvik KM; Gordeladze JO
Biosci Rep; 1993 Feb; 13(1):27-39. PubMed ID: 8392394
[TBL] [Abstract][Full Text] [Related]
5. Measurement of vitamin D3 metabolites in smelter workers exposed to lead and cadmium.
Chalkley SR; Richmond J; Barltrop D
Occup Environ Med; 1998 Jul; 55(7):446-52. PubMed ID: 9816377
[TBL] [Abstract][Full Text] [Related]
6. Effect of 1,25-dihydroxy-vitamin D3 in itself or combined with hormone treatment in preventing postmenopausal osteoporosis.
Christiansen C; Christensen MS; Rødbro P; Hagen C; Transbøl I
Eur J Clin Invest; 1981 Aug; 11(4):305-9. PubMed ID: 6795047
[TBL] [Abstract][Full Text] [Related]
7. Effect of vitamin D metabolites on bone metabolism in a rat model of postmenopausal osteoporosis.
Matsumoto T; Ezawa I; Morita K; Kawanobe Y; Ogata E
J Nutr Sci Vitaminol (Tokyo); 1985 Dec; 31 Suppl():S61-5. PubMed ID: 3915757
[TBL] [Abstract][Full Text] [Related]
8. Effect of 24,25-dihydroxyvitamin D3 on 1,25-dihydroxyvitamin D3 metabolism in calcium-deficient rats.
Matsumoto T; Ikeda K; Yamato H; Morita K; Ezawa I; Fukushima M; Nishii Y; Ogata E
Biochem J; 1988 Mar; 250(3):671-7. PubMed ID: 2839142
[TBL] [Abstract][Full Text] [Related]
9. Lack of seasonal variation in bone mass and biochemical estimates of bone turnover.
Overgaard K; Nilas L; Johansen JS; Christiansen C
Bone; 1988; 9(5):285-8. PubMed ID: 3203016
[TBL] [Abstract][Full Text] [Related]
10. Clinical, biochemical and histological results of a double-blind trial with 1,25-dihydroxyvitamin D3, estradiol and placebo in post-menopausal osteoporosis.
Caniggia A; Delling G; Nuti R; Lorè F; Vattimo A
Acta Vitaminol Enzymol; 1984; 6(2):117-28. PubMed ID: 6388277
[TBL] [Abstract][Full Text] [Related]
11. Effect of estrogen/gestagen and 24R,25-dihydroxyvitamin D3 therapy on bone formation in postmenopausal women.
Thomsen K; Riis B; Christiansen C
J Bone Miner Res; 1986 Dec; 1(6):503-7. PubMed ID: 3332556
[TBL] [Abstract][Full Text] [Related]
12. The effect of vitamin D on bone in vivo.
Tam CS; Heersche JN; Jones G; Murray TM; Rasmussen H
Endocrinology; 1986 Jun; 118(6):2217-24. PubMed ID: 3486118
[TBL] [Abstract][Full Text] [Related]
13. Does calcium supplementation prevent postmenopausal bone loss? A double-blind, controlled clinical study.
Riis B; Thomsen K; Christiansen C
N Engl J Med; 1987 Jan; 316(4):173-7. PubMed ID: 3540668
[TBL] [Abstract][Full Text] [Related]
14. Treatment of hemodialysis bone disease with 24,25-(OH)2D3 and 1,25-(OH)2D3 alone or in combination.
Dunstan CR; Hills E; Norman AW; Bishop JE; Mayer E; Wong SY; Eade Y; Johnson JR; George CR; Collett P
Miner Electrolyte Metab; 1985; 11(6):358-68. PubMed ID: 3877862
[TBL] [Abstract][Full Text] [Related]
15. Ability of 25-hydroxyvitamin D3 therapy to augment serum 1,25- and 24,25-dihydroxyvitamin D in postmenopausal osteoporosis.
Lawoyin S; Zerwekh JE; Glass K; Pak CY
J Clin Endocrinol Metab; 1980 Mar; 50(3):593-6. PubMed ID: 6965678
[TBL] [Abstract][Full Text] [Related]
16. Serum vitamin D metabolites are not related to growth rate, bone mineral content, or serum alkaline phosphatase in male puberty.
Krabbe S; Christiansen C; Hummer L
Calcif Tissue Int; 1986 Mar; 38(3):127-9. PubMed ID: 3085890
[TBL] [Abstract][Full Text] [Related]
17. Increase of bone volume in vitamin D-repleted rats by massive administration of 24R,25(OH)2D3.
Nakamura T; Kurokawa T; Orimo H
Calcif Tissue Int; 1988 Oct; 43(4):235-43. PubMed ID: 3145129
[TBL] [Abstract][Full Text] [Related]
18. Effect of vitamin D metabolites on the expression of alkaline phosphatase activity by epiphyseal hypertrophic chondrocytes in primary cell culture.
Hale LV; Kemick ML; Wuthier RE
J Bone Miner Res; 1986 Dec; 1(6):489-95. PubMed ID: 3509742
[TBL] [Abstract][Full Text] [Related]
19. Activity of ornithine decarboxylase and creatine kinase in soft and hard tissue of vitamin D-deficient chicks following parenteral application of 1,25-dihydroxyvitamin D3 or 24R,25-dihydroxyvitamin D3.
Ittel TH; Ross FP; Norman AW
J Bone Miner Res; 1986 Feb; 1(1):23-31. PubMed ID: 3509739
[TBL] [Abstract][Full Text] [Related]
20. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss.
Gallagher JC; Fowler SE; Detter JR; Sherman SS
J Clin Endocrinol Metab; 2001 Aug; 86(8):3618-28. PubMed ID: 11502787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
